https://www.selleckchem.com/pr....oducts/gsk2126458.ht
4) showed a better progression-free survival compared to patients with high NLR ( 4.4) (p = 0.01). IPA showed that the majority of immunity-related genes were found upregulated in responders compared to non-responders before treatment, but not after. Lymphocytes subpopulations, CECs and NLR could be interesting biomarkers predictive of response to everolimus-based regimens, potentially useful in daily clinical practice to select/monitor everolimus-based treatment in mBC. Further studies to confirm such hypotheses are warranted. L
Like
Comment
Share